Analyst Reco. CRISPR Therapeutics AG

Stocks

CRSP

CH0334081137

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 11/07/2026 am IST			5-day change	1st Jan Change
53.35 ^USD	-5.31%		-11.20%	+1.74%

30/06	CRISPR Therapeutics AG(NasdaqGM:CRSP) added to Russell Small Cap Comp Growth Benchmark	CI
30/06	CRISPR Therapeutics AG(NasdaqGM:CRSP) added to Russell 2500 Growth Benchmark	CI

Analyst Reco.

22/01	BofA Securities Adjusts Price Target on CRISPR Therapeutics AG to $89 From $90, Maintains Buy Rating	MT
06/01	BofA Adjusts Price Target on CRISPR Therapeutics to $90 From $93, Maintains Buy Rating	MT
26/11	Chardan Cuts Price Target on CRISPR Therapeutics to $74 From $82, Keeps Buy Rating	MT
11/11	RBC Raises Price Target on CRISPR Therapeutics to $50 From $42, Keeps Sector Perform, Speculative Risk	MT
05/11	Wedbush Adjusts CRISPR Therapeutics Price Target to $9 From $13, Maintains Outperform Rating	MT
17/25/17	BofA Securities Adjusts Price Target on CRISPR Therapeutics AG to $93 From $78, Maintains Buy Rating	MT
18/25/18	JPMorgan Initiates Coverage on CRISPR Therapeutics With Overweight Rating, $70 Price Target	MT
08/25/08	Truist Securities Adjusts Price Target on CRISPR Therapeutics to $100 From $120, Maintains Buy Rating	MT
05/25/05	RBC Raises Price Target on CRISPR Therapeutics to $42 From $38, Keeps Sector Perform, Speculative Risk	MT
21/25/21	Mizuho Cuts Price Target on CRISPR Therapeutics to $85 From $99, Keeps Outperform Rating	MT
17/25/17	BofA Adjusts Price Target on CRISPR Therapeutics to $80 From $86, Keeps Buy Rating	MT
03/25/03	RBC Cuts Price Target on CRISPR Therapeutics to $38 From $48, Keeps Sector Perform, Speculative Risk	MT
12/25/12	Truist Securities Adjusts Price Target on CRISPR Therapeutics to $120 From $100, Keeps Buy Rating	MT
12/25/12	TD Cowen Upgrades CRISPR Therapeutics to Hold From Sell, Adjusts Price Target to $35 From $30	MT
12/25/12	RBC Lowers Price Target on CRISPR Therapeutics to $48 From $53, Keeps Sector Perform, Speculative Risk	MT
11/25/11	BofA Securities Adjusts CRISPR Therapeutics Price Target to $86 From $85, Maintains Buy Rating	MT
03/25/03	HC Wainwright Initiates CRISPR Therapeutics at Buy With $65 Price Target	MT
07/25/07	BofA Securities Adjusts Price Target on CRISPR Therapeutics to $85 From $98, Maintains Buy Rating	MT
04/24/04	RBC Cuts Price Target on CRISPR Therapeutics to $53 From $60, Keeps Sector Perform Rating	MT
12/24/12	Truist Adjusts Price Target on CRISPR Therapeutics to $100 From $120, Maintains Buy Rating	MT
08/24/08	Morgan Stanley Cuts Price Target on CRISPR Therapeutics to $45 From $50, Keeps Underweight Rating	MT
06/24/06	RBC Cuts Price Target on CRISPR Therapeutics to $60 From $66, Keeps Sector Perform, Speculative Risk	MT
06/24/06	Chardan Research Adjusts Price Target on CRISPR Therapeutics to $94 From $112, Maintains Buy Rating	MT
02/24/02	Rodman & Renshaw Initiates CRISPR Therapeutics at Buy With $90 Price Target	MT
10/24/10	Oppenheimer Adjusts CRISPR Therapeutics Price Target to $95 From $102, Maintains Outperform Rating	MT